Evidence map›Paper›PMID 40363835›Full record

ArticleMolecules (Basel, Switzerland)2025

Synthesis and Biological Evaluation of Novel Ramalin Derivatives as Multi-Target Agents for Alzheimer's Disease.

Tai Kyoung Kim, Ju-Mi Hong, Yongeun Cho, Yeji Jeon, Heewon Cho, Jeongmi Lee, Jaewon Kim, Kyung Hee Kim, Il-Chan Kim, Se Jong Han and 3 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tai Kyoung KimCRYOTECH Inc., 2F-211-3, 71 Mieumsandan 5-ro 41beon-gil, Gangseo-gu, Busan 46744, Republic of Korea.
Ju-Mi HongDivision of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Republic of Korea.ORCID 0000-0003-2409-9968
Yongeun ChoSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0009-0005-1837-9885
Yeji JeonSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Heewon ChoSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Jeongmi LeeSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0000-0002-4134-5713
Jaewon KimDivision of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Republic of Korea.ORCID 0009-0004-1184-3908
Kyung Hee KimDivision of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Republic of Korea.
Il-Chan KimDivision of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Republic of Korea.ORCID 0000-0002-5776-7582
Se Jong HanDivision of Polar Life Sciences, Korea Polar Research Institute, Incheon 21990, Republic of Korea.ORCID 0000-0001-9576-2179
Hyuncheol OhCollege of Pharmacy, Wonkwang University, Iksan 54538, Republic of Korea.
Dong-Gyu JoSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0000-0003-2271-1076
Joung Han YimCRYOTECH Inc., 2F-211-3, 71 Mieumsandan 5-ro 41beon-gil, Gangseo-gu, Busan 46744, Republic of Korea.ORCID 0000-0003-4415-1778

Funding

Korea Polar Research Institute KOPRI PE25160Ministry of Oceans and Fisheries RS-2021-KS211513
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by cognitive decline, oxidative stress, neuroinflammation, amyloid-beta (Aβ) accumulation, and tau protein hyperphosphorylation. In this study, we synthesized novel Ramalin derivatives and evaluated their therapeutic potential against AD, focusing on antioxidant, anti-inflammatory, and neuroprotective activities. RA-2OMe, RA-4OMe, RA-2CF3, and RA-4OCF3 showed strong antioxidant effects, while RA-2OMe exhibited potent NO and NLRP3 inhibition (~20%). RA-NAP, RA-PYD, and RA-2Q showed moderate anti-inflammatory activity. BACE-1 inhibition was significant in RA-3CF3, RA-NAP, and RA-PYD, with IC

Indexed as

Alzheimer DiseaseNeuroprotective AgentsAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAnimalsAnti-Inflammatory AgentsAntioxidantsAspartic Acid EndopeptidasesHumansMiceOxidative Stresstau ProteinsAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAnti-Inflammatory AgentsAntioxidantsAspartic Acid EndopeptidasesNeuroprotective Agentstau ProteinsAlzheimer’s diseaseanti-inflammatory activityantioxidant activityBACE-1 inhibitionmulti-target therapyRamalin derivativestau aggregation

Identifiers

PMID40363835
PMCPMC12073177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.